This position is responsible for ensuring that the final product observes the company’s quality standards and for the development and implementation of inspection activities, the detection and resolution of problems, and the delivery of quality product.

Endo combined with Mallinckrodt Pharmaceuticals in 2025 to better serve customers and improve outcomes for the patients we support.
From this union, we established two focused, standalone companies:
– Keenova Therapeutics, a branded therapeutics business
– Par Health, a generics and sterile injectables business
To learn more, follow Keenova and Par Health on LinkedIn and visit keenova.com and parhealth.com.